Name: Market drivers behind the company’s strong performance, including a growing realisation among drug developers of the value of human challenge trials
Uploaded: 2023-01-25T07:55:07.534434+00:00
Duration: 647 s
Channel: Vox Markets
Description: Market drivers behind the company’s strong performance, including a growing realisation among drug developers of the value of human challenge trials

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/005/662/005662/video_Vt30niW.mp4#t=124

Vox Markets

Market drivers behind the company’s strong performance, including a  growing realisation among drug developers of the value of human challenge  trials

Highlights of the trading update, and drivers behind an exceptional ahead- of-expectations performance

Delivering the huge order backlog and growing the pipeline of potential new deals, and the coming launch of new challenge models

hVIVO’s unique model, and why as a world leader in human challenge trials  it’s becoming a critical component of drug development

Discusses the recent Venn Life Sciences consultancy contract win

Using strengthening cash generation to start paying a dividend alongside  continued investment in growth

Vox Markets speaks to Mo Khan, chief executive of fast-growing clinical research specialist hVIVO, about the factors behind an expectation-beating year, and how rising awareness of its unique human challenge model points to major growth ahead.

0:29 Highlights of the trading update, and drivers behind an exceptional ahead-of-expectations performance
2:04 Market drivers behind the company’s strong performance, including a growing realisation among drug developers of the value of human challenge trials
3:59 Delivering the huge order backlog and growing the pipeline of potential new deals, and the coming launch of new challenge models
6:35 hVIVO’s unique model, and why as a world leader in human challenge trials it’s becoming a critical component of drug development
8:04 Discusses the recent Venn Life Sciences consultancy contract win
9:02 Using strengthening cash generation to start paying a dividend alongside continued investment in growth

Vox Markets speaks to Mo Khan, chief executive of fast-growing clinical research specialist hVIVO, about the factors behind an expectation-beating year, and how rising awareness of its unique human challenge model points to major growth ahead.0:29 Highlights of the trading update, and drivers behind an exceptional ahead-of-expectations performance 2:04 Market drivers behind the company’s strong performance, including a growing realisation among drug developers of the value of human challenge trials 3:59 Delivering the huge order backlog and growing the pipeline of potential new deals, and the coming launch of new challenge models 6:35 hVIVO’s unique model, and why as a world leader in human challenge trials it’s becoming a critical component of drug development 8:04 Discusses the recent Venn Life Sciences consultancy contract win 9:02 Using strengthening cash generation to start paying a dividend alongside continued investment in growth

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/005/662/005662/video_Vt30niW.mp4